HM61713

· Hanmi Pharmaceutical Company Limited

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for HM61713, covering 2018-04-24 to 2018-04-24. Get the full timeline:

Most recent: Clinical Trial Update: Phase II Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line NSCLC Anticancer Therapy [Phase 2]